Abrams P, Andersson K-E, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40.

Article  PubMed  CAS  Google Scholar 

Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61(Suppl 1):S33–42.

Article  PubMed  Google Scholar 

Apostolidis A, Papaefstathiou E, Gatsos S. Intravesical Botox for overactive bladder: how to minimize complications and manage failures. Curr Drug Targets. 2020;21(15):1527–36.

Article  PubMed  CAS  Google Scholar 

Stewart W, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.

Article  PubMed  CAS  Google Scholar 

Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5):7–12.

Article  PubMed  Google Scholar 

Liu H-T, Chancellor MB, Kuo H-C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009;56(4):700–7.

Article  PubMed  CAS  Google Scholar 

Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174(3):984–9.

Article  PubMed  CAS  Google Scholar 

Gong QQ, Xu YQ, Xu J, Ding XY, Guo C. Meta-analysis of randomized controlled trials using botulinum toxin A at different dosages for urinary incontinence in patients with overactive bladder. Front Pharmacol. 2020;15(10):1618.

Article  Google Scholar 

Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63.

Article  PubMed  Google Scholar 

Kelsey E, Wynn J, Holmes A, McLeod K. Anatomical location and number of injection sites of intravesical OnabotulinumtoxinA for females with refractory idiopathic overactive bladder: a scoping review. Neurourol Urodyn. 2024;7:100957.

Google Scholar 

Defreitas GA, Zimmern PE, Lemack GE, Shariat SF. Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology. 2004;64(4):675–9.

Article  PubMed  Google Scholar 

Rosier PF, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, Dickinson T, Hashim H. International Continence Society Good Urodynamic Practices and Terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36(5):1243–60.

Article  PubMed  Google Scholar 

Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608–15.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rapp DE, Lucioni A, Bales GT. Botulinum toxin injection: a review of injection principles and protocols. Int Braz J Urol. 2007;33:132–41.

Article  PubMed  Google Scholar 

Avallone MA, Sack BS, El-Arabi A, Guralnick ML, O'Connor RC. Less is more—A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity. Neurourol Urodyn. 2017;36(4):1104–7.

Article  PubMed  CAS  Google Scholar 

Karsenty G, Carsenac A, Boy S, Reitz A, Bardot P, Tournebise H, et al. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-A prospective randomized study to compare 30 vs. 10 injection sites. Eur Urol Suppl. 2007;2(6):245.

Article  Google Scholar 

Coelho A, Cruz F, Cruz CD, Avelino A. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012;61(6):1178–84.

Article  PubMed  CAS  Google Scholar 

Chen S-F, Chang C-H, Kuo H-C. Clinical efficacy and changes of urothelial dysfunction after repeated detrusor botulinum toxin A injections in chronic spinal cord-injured bladder. Toxins. 2016;8(6):164.

Article  PubMed  PubMed Central  Google Scholar 

Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, Schurch B. A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol. 2009;27(3):397–403.

Article  PubMed  CAS  Google Scholar 

Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. Neurourol Urodyn. 2016;35(6):717–23.

Article  PubMed  CAS  Google Scholar 

Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units Dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2017;36(2):457–62.

Article  PubMed  CAS  Google Scholar 

Martínez-Cuenca E, Bonillo MA, Morán E, Broseta E, Arlandis S. OnabotulinumtoxinA re-injection for refractory detrusor overactivity using 3–4 injection sites: results of a pilot study. Urology. 2020;137:50–4.

Article  PubMed  Google Scholar 

Ton J, Downing P, Versi E, van Uem S, Ephraim S, Murphy M, Lucente V. Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB). Int Urol Nephrol. 2021;53(6):1067–72.

Article  PubMed  CAS  Google Scholar 

Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65(5):981–90.

Article  PubMed  CAS  Google Scholar 

Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43:16–24.

Article  Google Scholar